Skip to main content

Table 1 Patient characteristics and clinicopathological variables for the study population and samples included in PCR validation

From: Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study

Characteristic

NOWAC pilot study

Study population

PCR analyses

Cases N (%)

Controls N (%)

Cases N (%)

Controls N (%)

Study subjects

108 (100)

44 (100)

40 (100)

20 (100)

Age (years)

 ≤ 50

7 (6.5)

1 (2.3)

1 (2.5)

1 (5.0)

 > 50

101 (93.5)

43 (97.7)

39 (97.5)

19 (95.0)

Tumor grade

 1

34 (31.5)

–

7 (17.5)

–

 2

42 (38.9)

–

17 (42.5)

–

 3

28 (25.9)

–

16 (40.0)

–

 Unknown

4 (3.7)

 

0 (0)

 

Tumor size (mm)

 0–10

23 (21.3)

–

2 (5.0)

–

 10–20

50 (46.3)

–

24 (60.0)

–

 > 20

34 (31.5)

–

14 (35.0)

–

 Unknown

1 (0.9)

 

0 (0)

 

Lymph node status

 N0

73 (67.6)

–

30 (75.0)

–

 N+

34 (31.5)

–

10 (25.0)

–

 Unknown

1 (0.9)

–

0 (0)

–

Hormone receptor status

 ER/PR positive

81 (75.0)

–

23 (57.5)

–

 ER/PR negative

27 (25.0)

–

17 (42.5)

–

 Unknown

0 (0)

–

0 (0)

–

HER2 receptor status

 HER2 positive

20 (18.5)

–

15 (37.5)

–

 HER2 negative

86 (79.6)

–

25 (62.5)

–

 Unknown

2 (1.9)

–

0 (0)

–

Molecular subtype

 Luminal A

58 (53.7)

–

12 (30.0)

–

 Luminal B

22 (20.4)

–

11 (27.5)

–

 HER2 positive

9 (8.3)

–

7 (17.5)

–

 Triple-negative

16 (14.8)

–

10 (25.0)

–

 Unknown

3 (2.8)

 

0 (0)

 

Histological type

 Infiltrating carcinoma NST

92 (85.2)

–

35 (87.5)

–

 Lobular carcinoma

10 (9.3)

–

3 (7.5)

–

 Tubular

3 (2.8)

–

0 (0)

–

 Other

3 (2.8)

–

2 (5.0)

–